NEW BRUNSWICK, N.J. – U.S. regulators have approved use of a powerful Johnson & Johnson antibiotic to treat plague, an extremely rare, sometimes-deadly bacterial infection.
The Food and Drug Administration also approved Levaquin, known generically as levofloxacin, to reduce risk of people getting plague after exposure to the bacteria that cause it. Called Yersinia pestis, the bacteria are considered a potential bioterrorism agent.
Plague mainly occurs in animals. People can get it from bites from infected fleas or contact with infected animals or humans. About 1,000 to 2,000 human cases occur worldwide each year.
The FDA approved Levaquin for plague after tests on African green monkeys infected with the bacteria in a lab found 94 percent of the monkeys given Levaquin survived.
Notice about comments:
The Post and Courier is pleased to offer readers the enhanced ability to comment on stories. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We ask that you refrain from profanity, hate speech, personal comments and remarks that are off point.